Get the Stockscreener App
7.84
2.75%
0.21
Novavax Inc stock is traded at $7.84, with a volume of 8.45M.
It is up +2.75% in the last 24 hours and up +8.59% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$7.63
Open:
$7.74
24h Volume:
8.45M
Relative Volume:
1.11
Market Cap:
$1.27B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
3.4386
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
-18.16%
1M Performance:
+8.59%
6M Performance:
-1.88%
1Y Performance:
-34.45%
1-Day Range:
$7.605
$8.075
1-Week Range:
$7.57
$10.64
52-Week Range:
$5.01
$15.22
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.84 | 1.58B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions - insights.citeline.com
Is It Too Late to Sell Novavax Inc.July 2025 Reactions & Reliable Entry Point Alerts - kangso.co.kr
BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9 - MarketScreener
Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls - Yahoo Finance
Novavax downgraded to Underperform at BofA on growth uncertainties - Seeking Alpha
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Novavax Inc. Flashes Rebound Signal in Oversold ConditionEarnings Overview Report & Advanced Technical Signal Analysis - classian.co.kr
CDC vaccines panel axed by RFK Jr. had conflicts of interest near historic lows (MRNA:NASDAQ) - Seeking Alpha
DC InnoThe Pitch: Meet interior design startup Deazly | Novavax gets CDC signoff - The Business Journals
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership - Yahoo Finance
MACD Signals Flash Warning for Novavax Inc. StockWeekly Stock Recap & Low Risk High Reward Ideas - newsimpact.co.kr
Is Novavax's (NVAX) Profit Swing Revealing a Shift in Its Long-Term Growth Strategy? - simplywall.st
Is This a Bottoming Phase for Novavax Inc.2025 Sector Review & Free High Return Stock Watch Alerts - newsyoung.net
Novavax slips as Citi launches with Sell rating on pipeline concerns - MSN
Novavax Stock Soars Amid Strategic Milestones - TipRanks
NOVAVAX, INC. (NVAX) - MSN
Notable Thursday Option Activity: APAM, GRPN, NVAX - Nasdaq
Novavax Inc. Nearing Breakout Level After BouncePortfolio Risk Report & Real-Time Buy Signal Notifications - beatles.ru
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 27% But Its Business Still Trails The Industry - 富途牛牛
Price Reversal in Novavax Inc. Traders Watch CloselyBond Market & Weekly High Conviction Ideas - thegnnews.com
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - MSN
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - ADVFN Brasil
Why Novavax (NVAX) Is Up 26.0% After Surging Year-to-Date Profits Despite Lower Quarterly Results - simplywall.st
Novavax's 2025 Q2 Earnings Call: Navigating Key Contradictions in CIC Strategy and Regulatory Pathways - AInvest
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
Biotech sector slips amid reported return of ousted FDA official (SRPT:NASDAQ) - Seeking Alpha
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk - Benzinga
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View - MSN
Novavax Stock Surges 24% Amid Milestone Payment and Strategic Gains - AInvest
Here are the 50 largest bioscience employers in Greater Washington - The Business Journals
Novavax Earnings Call: Milestones and Challenges - The Globe and Mail
Novavax shares rise 15.37% intraday as rival Moderna's shares fall due to government winding down mRNA vaccine-development activities. - AInvest
Novavax’s Q2 Financial Success: A Game Changer? - StocksToTrade
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Novavax Reports Strong Earnings Amid Strategic Shifts - TipRanks
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax: Q2 Earnings Snapshot - Connecticut Post
Novavax Q2 2025 Earnings Call Transcript - MarketBeat
Novavax (NVAX) Profit Jumps on Milestone - The Globe and Mail
Novavax raises 2025 revenue target to $1.05B with milestone payments and streamlined expenses as Sanofi partnership progresses - MSN
Novavax higher after Q2 beat as partnerships brighten outlook - MSN
Novavax (NVAX) Reports Q2 Progress and Key Partnership Developme - GuruFocus
Transcript : Novavax, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Novavax expects post-marketing Covid study to cost up to $90M - Endpoints News
Novavax stock surges as HHS pulls mRNA vaccine funding, opening doors for alternative technologies - The Business Journals
Novavax outlook 2025 adjusted revenue $1 bln to $1.05 bln versus IBES estimate $1.02 bln - MarketScreener
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification - Investing.com India
Novavax banks on vaccine supply partnerships to boost 2025 revenue - Reuters
Novavax Shares Rise Following Avian Flu Vaccine Success - StocksToTrade
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):